Enzon Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 0.213 million compared to USD 0.019 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
For the six months, net loss was USD 0.504 million compared to USD 0.008 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago.